Literature DB >> 15314220

Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier.

Akihiko Urayama1, Jeffrey H Grubb, William S Sly, William A Banks.   

Abstract

Mucopolysaccharidosis type VII is a pan class="Disease">lysosomal storage disorder resulting from inherited deficiency of beta-glucuronidase (GUS). Mucopolysaccharidosis type VII is characterized by glycosaminoglycan storage in most tissues, including brain. In these disorders, enzyme delivery across the blood-brain barrier (BBB) is the main obstacle to correction of lysosomal storage in the CNS. Prior studies suggested mouse brain is accessible to GUS in the first 2 weeks of life but not later. To explore a possible role for the mannose 6-phosphate/insulin-like growth factor II receptor in GUS transport across the BBB in neonatal mice, we compared brain uptake of phosphorylated GUS (P-GUS) and nonphosphorylated GUS (NP-GUS) in newborn and adult mice. (131)I-P-GUS was transported across the BBB after i.v. injection in 2-day-old mice. The brain influx rate (K(in)) of (131)I-P-GUS in 2-day-old mice was 0.21 microl/g.min and decreased with age. By 7 weeks of age, transport of (131)I-P-GUS was not significant. Capillary depletion revealed that 62% of the (131)I-P-GUS in brain was in brain parenchyma in 2-day-old mice. In addition, uptake of (131)I-P-GUS into brain was significantly reduced by coinjection of unlabeled P-GUS or M6P in a dose-dependent manner. In contrast, the K(in) of (131)I-NP-GUS (0.04 microl/g.min) was significantly lower than (131)I-P-GUS in 2-day-old mice. Transcardiac brain perfusion confirmed that neither (131)I-P-GUS nor (131)I-NP-GUS crossed the BBB in adult mice. These results indicate that (131)I-P-GUS transport into brain parenchyma in early postnatal life is mediated by the mannose 6-phosphate/insulin-like growth factor II receptor. This receptor-mediated transport is not observed in adult mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15314220      PMCID: PMC515112          DOI: 10.1073/pnas.0405042101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  PURIFICATION AND PROPERTIES OF HUMAN LIVER BETA-GLUCURONIDASE.

Authors:  B U MUSA; R P DOE; U S SEAL
Journal:  J Biol Chem       Date:  1965-07       Impact factor: 5.157

2.  The type II insulin-like growth factor receptor is internalized and recycles in the absence of ligand.

Authors:  Y Oka; M P Czech
Journal:  J Biol Chem       Date:  1986-07-15       Impact factor: 5.157

3.  Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.

Authors:  C Vogler; M S Sands; B Levy; N Galvin; E H Birkenmeier; W S Sly
Journal:  Pediatr Res       Date:  1996-06       Impact factor: 3.756

4.  Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins.

Authors:  D Triguero; J Buciak; W M Pardridge
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

Review 5.  Mammalian beta-glucuronidase: genetics, molecular biology, and cell biology.

Authors:  K Paigen
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1989

6.  Demonstration and structural comparison of receptors for insulin-like growth factor-I and -II (IGF-I and -II) in brain and blood-brain barrier.

Authors:  R G Rosenfeld; H Pham; B T Keller; R T Borchardt; W M Pardridge
Journal:  Biochem Biophys Res Commun       Date:  1987-11-30       Impact factor: 3.575

7.  Purification and properties of beta-glucuronidase from human placenta.

Authors:  F E Brot; C E Bell; W S Sly
Journal:  Biochemistry       Date:  1978-02-07       Impact factor: 3.162

8.  Developmental regulation of insulin-like growth factor-II/mannose 6-phosphate receptor mRNA in the rat.

Authors:  M Ballesteros; C D Scott; R C Baxter
Journal:  Biochem Biophys Res Commun       Date:  1990-10-30       Impact factor: 3.575

9.  Receptor binding, endocytosis, and mitogenesis of insulin-like growth factors I and II in fetal rat brain neurons.

Authors:  F C Nielsen; E Wang; S Gammeltoft
Journal:  J Neurochem       Date:  1991-01       Impact factor: 5.372

10.  Expression of the IGF-II/mannose-6-phosphate receptor mRNA and protein in the developing rat.

Authors:  P V Senior; S Byrne; W J Brammar; F Beck
Journal:  Development       Date:  1990-05       Impact factor: 6.868

View more
  81 in total

1.  Pharmacologic manipulation of lysosomal enzyme transport across the blood-brain barrier.

Authors:  Akihiko Urayama; Jeffrey H Grubb; William S Sly; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-03       Impact factor: 6.200

2.  Modifying blood-brain barrier transport to bring hope for patients with lysosomal storage diseases.

Authors:  Richard F Keep; Jianming Xiang
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-04       Impact factor: 6.200

3.  Exosomes as drug delivery vehicles for Parkinson's disease therapy.

Authors:  Matthew J Haney; Natalia L Klyachko; Yuling Zhao; Richa Gupta; Evgeniya G Plotnikova; Zhijian He; Tejash Patel; Aleksandr Piroyan; Marina Sokolsky; Alexander V Kabanov; Elena V Batrakova
Journal:  J Control Release       Date:  2015-03-31       Impact factor: 9.776

4.  A breach in the blood-brain barrier.

Authors:  Jonathan H Lebowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

Review 5.  Gene therapy for glycogen storage diseases.

Authors:  Priya S Kishnani; Baodong Sun; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 6.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

7.  Targeted delivery of proteins across the blood-brain barrier.

Authors:  Brian J Spencer; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

8.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

9.  Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.

Authors:  Ulrich Matzner; Renate Lüllmann-Rauch; Stijn Stroobants; Claes Andersson; Cecilia Weigelt; Carl Eistrup; Jens Fogh; Rudi D'Hooge; Volkmar Gieselmann
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

10.  Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier.

Authors:  Daren Wang; Salim S El-Amouri; Mei Dai; Chia-Yi Kuan; David Y Hui; Roscoe O Brady; Dao Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.